Fate Therapeutics to Present FT522 Autoimmune Disease Data at ASGCT

Fate Therapeutics Inc., a clinical-stage biopharmaceutical firm, has announced the presentation of preclinical data from its FT522 program at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting. The event will take place in Baltimore, Maryland, from May 7-11, 2024.

FT522 is an innovative CD19-targeted, induced pluripotent stem cell (iPSC)-derived chimeric antigen receptor (CAR) natural killer (NK) cell product. It integrates Fate Therapeutics’ proprietary alloimmune defense receptor (ADR) technology. This technology is designed to enhance the potency of off-the-shelf cell therapies, allowing treatment without the necessity of conditioning chemotherapy.

At the ASGCT conference, Fate Therapeutics will present multiple preclinical studies. These studies will use peripheral blood mononuclear cells (PBMCs) sourced from unmatched donors suffering from systemic lupus erythematosus (SLE). The data from these studies show that FT522 can achieve rapid and significant depletion of B cells, improved functional persistence, and eliminate alloreactive host immune cells. This indicates that FT522 may offer therapeutic benefits for patients with autoimmune diseases without the need for conditioning chemotherapy.

The details for the presentation are as follows:
- Presentation: FT522: A CAR NK Cell with the Unique Ability to Target Multiple Pathogenic Cell Types and Circumvent Lympho-conditioning in Systemic Autoimmunity
- Late-Breaking Abstract Number: LBA-35
- Session: Late-Breaking Abstracts
- Location: Exhibit Hall
- Presentation Date/Time: Thursday, May 9, 2024, 12:00 PM

Fate Therapeutics’ iPSC product platform is at the core of this innovation. Human iPSCs have the unique ability to self-renew indefinitely and differentiate into any cell type in the body. The company's platform combines the engineering of human iPSCs with single-cell selection to create clonal master iPSC lines. These master lines are used to mass-produce engineered cell products that are consistent and can be stored for off-the-shelf availability. This approach potentially allows for the treatment of a broad patient population and can be administered alongside other therapies.

Moreover, this platform overcomes many limitations associated with using patient- or donor-sourced cells for cell therapy manufacturing. Fate Therapeutics has a strong intellectual property portfolio with over 500 issued patents and 500 pending patent applications supporting its iPSC product platform.

Fate Therapeutics is a leader in the clinical development of iPSC-derived cell products, focusing on creating CAR NK cell and T-cell product candidates. These candidates are selectively designed to incorporate novel synthetic controls of cell function and deliver multiple therapeutic mechanisms to patients. The company is based in San Diego, California, and continues to advance its pipeline of iPSC-derived cellular immunotherapies to treat cancer and autoimmune diseases.